Who is sponsoring NCT02604823?

NCT02604823 is sponsored by Hoffmann-La Roche.

What condition does NCT02604823 study?

NCT02604823 studies Hepatitis B, Chronic.

What drugs are being tested in NCT02604823?

Interventions: Peginterferon alfa-2a.

What is the status of NCT02604823?

NCT02604823 is currently COMPLETED.

Last reviewed 2016-11-01 · How we verify

Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (Pegasys®) in Patients With HBeAg-Positive Chronic Hepatitis B

NCT02604823 Phase 4 COMPLETED

This is a study of the efficacy and safety of peginterferon alfa-2a (Pegasys) in naive, interferon- or lamivudine-pretreated participants with HBeAg-positive chronic HBV. Following 48 weeks treatment, there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Details

Lead sponsor	Hoffmann-La Roche
Phase	Phase 4
Status	COMPLETED
Enrolment	307
Start date	2003-11
Completion	2005-11

Conditions

Hepatitis B, Chronic

Interventions

Peginterferon alfa-2a

Primary outcomes

Percentage of participants with HBV deoxyribonucleic acid (DNA) less than (<) 100,000 copies per milliliters (copies/mL) — 72 weeks
Percentage of participants with HBeAg seroconversion — 72 weeks

Countries

China